13-Community Acquired Pneumonia
13-Community Acquired Pneumonia
13-Community Acquired Pneumonia
.
CAP: Influenza
• First worlwide pandemic of H1N1 Influenza A (2009-2010)
• Ongoing epidemic in Saudi Arabia
• H1N1 risk factors
– pregnant, obesity, cardipulmonary disease, chronic renal disease,
chronic liver disease
• CXR findings often subtle, to full blown ARDS
• Respiratory (or Droplet) isolation for suspected or
documented influenza (Wear mask and gloves)
• NP swab for, Rapid Ag test Influ A,B. H1N1 PCR RNA
• Current Seasonal Influenza Vaccine prevents disease (given
every season)
• Bacterial pnemonia (S. pneumo, S. aureus) may follow viral
pneumonia
Influenza: Therapy
Neuraminidase Oseltamivir / 75mg po bid Influenza A, B
inhibitors Tamiflu
• Chlamydophila
psittaci
• Exposure to birds
• Bird owners, pet
shop employees, vets
• 1st: Tetracycline
• Alt: Macrolide
Tularemia
• Francisella tularensis
• Rabbits, squirrels, rodents
• Landscapers, Hunters
• Treat: streptomycin
Who is at risk for Pseudomonal
Pneumonia?
• Immunocompromised pts (HIV, solid organ or bone marrow
transplant, neutropenic, chronic oral steroids)
• Alcoholics
• Frequent prior antibiotic use
• Recent hospital admission
• Structural lung abnormalities
– Cystic fibrosis, bronchiectasis, severe COPD
– Prophylaxis with tobramycin nebs
• Rare in previously healthy pts
**Gram stain/sputum culture (if good quality) is usually
adequate to exclude need for empiric coverage
*** Treatment: Ceftazidime, cefepime, pip/tazo, amikacin,
tobramycin, aztreonam, ciprofloxacin, carbapenems,
Polymixin B
Who is at risk for Acinetobacter
Pneumonia?
• CAP
– Alcoholics
– Smoking
– Chronic lung disease
– DM
– Residence in tropical developing country
• HAP
– Admission to burns unit or ICU
– Mechanical ventilation
– Length of hospital stay
– Surgey
– Wounds
– Previous infection (independent of previous Abx use)
– Fecal colonization with Acinetobacter
– Treatment with broad spectrum antibiotics
– Indwelling central intravenous or urinary catheters
– Parenteral nutrition
• Treatment: Polymixin B (colistin), tigecycline
Who is at risk for which pathogens?
• Pnemonia in nursing home/long term care
facility residents similar to pneumonia in
hospitalized pts:
– Pseudomonas, Acinetobacter, MRSA
• Chronic hemodialysis:
– Increased risk of MRSA (not Pseudomonas or
Acinetobacter)
• COPD:
– Increased risk for Pseudomonas (not MRSA)
Remember these associations:
• Asplenia: Strep pneumo, H. influ.
• Alcoholism: Strep pneumo, oral anaerobes, K. pneumo.,
Acinetobacter, MTB
• COPD/smoking: H. influenzae, Pseudomonas, Legionella,
Strep pneumo, Moraxella catarrhalis, Chlamydophila
pneumoniae
• Aspiration: Klebsiella, E. Coli, oral anaerobes
• HIV: S. pneumo, H. influ, P. aeruginosa, MTB, PCP, Crypto,
Histo, Aspergillus, atypical mycobacteria
• Recent hotel, cruise ship: Legionella
• Structural lung disease (bronchiectasis): Pseudomonas
aerogenosa, Burkholderia cepacia, Staph. aureus
Pneumonia: Outpatient or Inpatient?
• CURB-65
– 5 indicators of increased mortality: confusion, BUN >7, RR
>30, SBP <90 or DBP <60, age >65
– Mortality: 2 factors9%, 3 factors15%, 5 factors57%
– Score 0-1outpt. Score 2inpt. Score >3ICU.
• Pneumonia Severity Index (PSI)
– 20 variables including underlying diseases; stratifies pts
into 5 classes based on mortality risk
• No RCTs comparing CURB-65 and PSI
Pneumonia: Medical floor or ICU?
• 1 major or 3 minor criteria= severe CAPICU
• Major criteria:
– Invasive ventilation, septic shock on pressors
• Minor criteria:
– RR>30; multilobar infiltrates; confusion; BUN >20;
WBC <4,000; Platelets <100,000; Temp <36,
hypotension requiring aggressive fluids,
PaO2/FiO2 <250.
• No prospective validation of these criteria
CAP Inpatient therapy
• General medical floor:
– Respiratory quinolone OR
– IV β-lactam PLUS macrolide (IV or PO)
• β-lactams: cefotaxime, ceftriaxone, ampicillin; ertapenem
• May substitute doxycycline for macrolide
• ICU:
– β-lactam (ceftriaxone, cefotaxime, Amox-clav) PLUS EITHER
quinolone OR azithro
– PCN-allergic: respiratory quinolone PLUS aztreonam
• Pseudomonal coverage :
– Antipneumococcal, antipseudomonal β-lactam (pip-tazo,
cefepime, imip, mero) PLUS EITHER (cipro or levo) OR
(aminoglycoside AND Azithro) OR (aminoglycoside AND
respiratory quinolone)
• CA-MRSA coverage: Vancomycin or Linezolid
CAP Inpatient Therapy: Pearls
• Give 1st dose Antibiotics in ER (no specified time frame)
• Switch from IV to oral when pts are hemodynamically
stable and clinically improving
• Discharge from hospital:
– As soon as clinically stable, off oxygen therapy, no active
medical problems
• Duration of therapy is usually 10-14 days:
– Treat for a minimum of 5 days
– Before stopping therapy: afebrile for 48-72 hours,
hemodynamically stable, RR <24, O2 sat >90%, normal mental
status
– Treat longer if initial therapy wasn’t active against identified
pathogen; or if complications (lung abscess, empyema)